Novacyt SA (Novacyt) is a medical device company that develops and markets in vitro and molecular diagnostic products for microbiology, hematology and serology. The company's products include genesig q16 and q32 real time PCR Instrument and the mygo qPCR instrument. It markets its products under the brands MyGo and genesig. Novacyt focusses on the clinical areas which cover a wide range of diseases including respiratory, gastrointestinal, insect-borne diseases, sexually transmitted infections (STIs), nosocomial infections, tropical fevers and hepatitis viruses. The company has collaboration with healthcare professionals, governments, individuals. It has operations in France and the UK. Novacyt is headquartered in Velizy Villacoublay, Ile-de-France, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Novacyt SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Novacyt SA Company Overview
- Novacyt SA Company Snapshot
- Novacyt SA Pipeline Products and Ongoing Clinical Trials Overview
- Novacyt SA - Pipeline Analysis Overview
- Novacyt SA - Key Facts
- Novacyt SA - Major Products and Services
- Novacyt SA Pipeline Products by Development Stage
- Novacyt SA Pipeline Products Overview
- Diagnostic Assay - Aspergillus
- Diagnostic Assay - Aspergillus Product Overview
- Diagnostic Assay - Pneumocystis
- Diagnostic Assay - Pneumocystis Product Overview
- Direct-To-PCR Extraction Device
- Direct-To-PCR Extraction Device Product Overview
- Genesig - Cytomegalovirus Test
- Genesig - Cytomegalovirus Test Product Overview
- Genesig Kit - Human Papillomavirus 14
- Genesig Kit - Human Papillomavirus 14 Product Overview
- Genesig q24
- Genesig q24 Product Overview
- LAMP COVID-19 Test
- LAMP COVID-19 Test Product Overview
- Multiplex Test - Mosquito-Borne Diseases
- Multiplex Test - Mosquito-Borne Diseases Product Overview
- Next Generation Lateral Flow Test - COVID-19
- Next Generation Lateral Flow Test - COVID-19 Product Overview
- Onconostica
- Onconostica Product Overview
- PathFlow COVID-19 Rapid Antigen Pro
- PathFlow COVID-19 Rapid Antigen Pro Product Overview
- PathFlow COVID-19 Rapid Antigen Self-Test
- PathFlow COVID-19 Rapid Antigen Self-Test Product Overview
- PathFlow SARS-CoV-2 Antigen Self-Test
- PathFlow SARS-CoV-2 Antigen Self-Test Product Overview
- PathFlow SARS-CoV-2 SMART IgG Test
- PathFlow SARS-CoV-2 SMART IgG Test Product Overview
- PROmate SARS-CoV-2 E484K Test
- PROmate SARS-CoV-2 E484K Test Product Overview
- Single Nucleotide Polymorphism Assay
- Single Nucleotide Polymorphism Assay Product Overview
- Two-Gene Target PROmate Test
- Two-Gene Target PROmate Test Product Overview
- Novacyt SA - Key Competitors
- Novacyt SA - Key Employees
- Novacyt SA - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Novacyt SA, Recent Developments
- Aug 22, 2024: Novacyt : Successful VAT reclaim of £12.2 million
- Jul 18, 2024: Novacyt : AGM Statement on Impact of DHSC Settlement
- Jun 11, 2024: Novacyt S.A Announces Settlement of the dispute with the DHSC
- May 20, 2024: Novacyt Notice of Results and AGM
- Apr 19, 2024: Novacyt SA Announces DHSC Claim update - Pre-Trial Review
- Jan 30, 2023: Novacyt : DHSC Claim update - Trial date listed
- Jan 19, 2023: CCL Announced as the Only Global Laboratory Partner For, First of Its Kind, Fertility Test
- Dec 06, 2022: Novacyt : Approval of genesig COVID-19 3G PCR test in the UK under CTDA legislation
- Oct 26, 2022: Novacyt : Approval of genesig SARS-CoV-2 Winterplex 3 Gene assay panel in the UK under CTDA legislation
- Jul 28, 2022: Launch of research-use-only adenovirus F41 assay
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Novacyt SA Pipeline Products and Ongoing Clinical Trials Overview
- Novacyt SA Pipeline Products by Equipment Type
- Novacyt SA Pipeline Products by Indication
- Novacyt SA, Key Facts
- Novacyt SA, Major Products and Services
- Novacyt SA Number of Pipeline Products by Development Stage
- Novacyt SA Pipeline Products Summary by Development Stage
- Diagnostic Assay - Aspergillus - Product Status
- Diagnostic Assay - Aspergillus - Product Description
- Diagnostic Assay - Pneumocystis - Product Status
- Diagnostic Assay - Pneumocystis - Product Description
- Direct-To-PCR Extraction Device - Product Status
- Direct-To-PCR Extraction Device - Product Description
- Genesig - Cytomegalovirus Test - Product Status
- Genesig - Cytomegalovirus Test - Product Description
- Genesig Kit - Human Papillomavirus 14 - Product Status
- Genesig Kit - Human Papillomavirus 14 - Product Description
- Genesig q24 - Product Status
- Genesig q24 - Product Description
- LAMP COVID-19 Test - Product Status
- LAMP COVID-19 Test - Product Description
- Multiplex Test - Mosquito-Borne Diseases - Product Status
- Multiplex Test - Mosquito-Borne Diseases - Product Description
- Next Generation Lateral Flow Test - COVID-19 - Product Status
- Next Generation Lateral Flow Test - COVID-19 - Product Description
- Onconostica - Product Status
- Onconostica - Product Description
- PathFlow COVID-19 Rapid Antigen Pro - Product Status
- PathFlow COVID-19 Rapid Antigen Pro - Product Description
- PathFlow COVID-19 Rapid Antigen Self-Test - Product Status
- PathFlow COVID-19 Rapid Antigen Self-Test - Product Description
- PathFlow SARS-CoV-2 Antigen Self-Test - Product Status
- PathFlow SARS-CoV-2 Antigen Self-Test - Product Description
- PathFlow SARS-CoV-2 SMART IgG Test - Product Status
- PathFlow SARS-CoV-2 SMART IgG Test - Product Description
- PROmate SARS-CoV-2 E484K Test - Product Status
- PROmate SARS-CoV-2 E484K Test - Product Description
- Single Nucleotide Polymorphism Assay - Product Status
- Single Nucleotide Polymorphism Assay - Product Description
- Two-Gene Target PROmate Test - Product Status
- Two-Gene Target PROmate Test - Product Description
- Novacyt SA, Key Employees
- Novacyt SA, Other Locations
- Novacyt SA, Subsidiaries
- Glossary
- Novacyt SA Pipeline Products by Equipment Type
- Novacyt SA Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Mauna Kea Technologies SAS
- Zimmer Biomet Robotics
- Eurobio Scientific SA
- Anagenesis Biotechnologies SAS
- AgCom biotech S.A.R.L.
- Stilla Technologies SAS
- Biosynex SA
